Marzola Pasquina, Ramponi Simona, Nicolato Elena, Lovati Emanuela, Sandri Marco, Calderan Laura, Crescimanno Caterina, Merigo Flavia, Sbarbati Andrea, Grotti Adriana, Vultaggio Stefania, Cavagna Friederich, Lorusso Vito, Osculati Francesco
Dipartimento di Scienze Morfologico-Biomediche, Sezione di Anatomia ed Istologia, Università di Verona, Verona.
Invest Radiol. 2005 Jul;40(7):421-9. doi: 10.1097/01.rli.0000167124.89782.db.
The aim of this study was to compare the efficacy of gadoteridol, B22956/1 (a new protein binding blood pool contrast agent), and (Gd-DTPA)37-albumin in detecting, by dynamic contrast-enhanced magnetic resonance imaging (MRI), the effect in vivo of tamoxifen in an experimental model of breast tumor implanted in rats.
Tumors were induced by subcutaneous injection of 10 mammary adenocarcinoma cells (13762 MAT B III). Treatment with tamoxifen (or vehicle) started on day 4 after implantation. On day 10 after implantation, animals were observed by MRI using B22956/1 (or gadoteridol) and, 24 hours later, using (Gd-DTPA)37-albumin.
Dynamic contrast-enhanced magnetic resonance imaging data showed that tamoxifen treatment decreased vascular permeability to B22956/1, whereas no difference was detectable in permeability to gadoteridol or to (Gd-DTPA)37-albumin. No effect on fractional plasma volume was detected with either of contrast agents.
B22956/1 is superior to both small Gd chelates and macromolecular contrast agents in the assessment of the effect of tamoxifen treatment on tumor vasculature.
本研究旨在通过动态对比增强磁共振成像（MRI），比较钆特醇、B22956/1（一种新型蛋白结合血池造影剂）和（钆喷酸葡胺）37 -白蛋白在检测他莫昔芬对大鼠植入性乳腺肿瘤实验模型体内作用方面的疗效。
通过皮下注射10个乳腺腺癌细胞（13762 MAT B III）诱导肿瘤形成。在植入后第4天开始用他莫昔芬（或赋形剂）进行治疗。在植入后第10天，使用B22956/1（或钆特醇）通过MRI观察动物，24小时后，使用（钆喷酸葡胺）37 -白蛋白进行观察。
动态对比增强磁共振成像数据显示，他莫昔芬治疗降低了肿瘤对B22956/1的血管通透性，而对钆特醇或（钆喷酸葡胺）37 -白蛋白的通透性未检测到差异。两种造影剂均未检测到对血浆分数容积的影响。
在评估他莫昔芬治疗对肿瘤血管系统的作用方面，B22956/1优于小分子钆螯合物和大分子造影剂。
